Mounjaro Tirzepatide

Tirzepatide beats Wegovy?
Tirzepatide for Weight Loss?
Costa Rica Doctors Perform Hormone Pellet Implants in Men & Women

Mounjaro Tirzepatide, better than Wegovy?

Tirzepatide is new drug recently approved by the FDA in May 2022 for the treatment of type 2 diabetes. It is a combination of two molecules: a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist and a dipeptidyl peptidase-4 (DPP-4) inhibitor. GLP-1 receptor agonists are a class of drugs that help to lower blood sugar levels by increasing insulin production and decreasing the amount of sugar produced by the liver. DPP-4 inhibitors work by preventing the breakdown of GLP-1, a hormone that helps to regulate blood sugar levels. Tirzepatide is currently approved for diabetes treatment, but may soon be in clinical trials for weight loss.

Tirzepatide was developed for the treatment of type 2 diabetes, and it is not specifically marketed as a weight loss medication.

However, tirzepatide may cause weight loss as a side effect, as some studies have shown that GLP-1 receptor agonists may lead to modest weight loss in people with type 2 diabetes.

GLP-1 receptor agonists work by increasing insulin production and decreasing the amount of sugar produced by the liver, which can help to lower blood sugar levels. They may also cause weight loss by decreasing appetite and increasing feelings of fullness. However, the exact mechanism by which GLP-1 receptor agonists cause weight loss is not fully understood and may be due to a combination of factors.

It is important to note that tirzepatide is a newly approved diabetes drug and has not yet been approved for use by regulatory agencies for weight loss. As such, it is not currently available for use and its potential effects on weight loss are not fully known. If you are interested in using medication for weight loss, it is important to speak with a healthcare provider to determine the best course of treatment for you.

When was Tirzepatide Approved by the FDA?

In May of 2022, The U.S. Food and Drug Administration (FDA) approved Mounjaro (tirzepatide) injection. The drug is manufactured by Eli Lilly. it is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. Both are considered incretin hormones. Its purpose is to improve glycemic control in adults with type 2 diabetes.

FDA Fast Tracks Tirzepatide for Obesity Patients

Lilly announced on Oct. 6 that the FDA granted tirzepatide a “fast track” review to be designated as a treatment for obesity. It’s expected that Tirzepatide could be approved as an obesity medication by 2023, and likely some doctors internationally will begin prescribing it before its approval date. 

What are incretin hormones?

Incretin hormones are hormones produced in the gut that stimulate the release of insulin in response to food intake. They also inhibit the production of glucagon, a hormone that stimulates the liver to produce and release glucose into the bloodstream. Incretin hormones play a key role in glucose homeostasis and blood sugar control.

There are two main types of incretin hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). GLP-1 is produced by L cells in the small intestine and colon, while GIP is produced by K cells in the small intestine. Both hormones are released in response to food intake, particularly the intake of carbohydrates.

GLP-1 and GIP have a number of effects on the body, including:

  • Increasing insulin production: Incretin hormones stimulate the pancreas to produce and release insulin in response to elevated blood sugar levels.
  • Decreasing appetite: Incretin hormones may also decrease appetite and increase feelings of fullness, which may lead to weight loss in some people.
  • Decreasing the production of glucose by the liver: Incretin hormones inhibit the production and release of glucose by the liver, which helps to lower blood sugar levels.
  • Incretin hormones are important regulators of blood sugar and are involved in the development of type 2 diabetes. They are also the target of several medications used to treat type 2 diabetes, including GLP-1 receptor agonists and DPP-4 inhibitors.

Trizepatide Weight Loss Not Indicated (Yet)...?

While not indicated for weight loss, mean change in body weight was a key secondary endpoint in all SURPASS studies. Participants treated with Mounjaro lost between 12 lb. (5 mg) and 25 lb. (15 mg) on average.

Mounjaro (Trizepatide) First Dual Action GIP / GLP-1 Combonation Medication

Tirzepatide for weight loss, maybe?

The first and only FDA-approved GIP and GLP-1 receptor agonist, Mounjaro is a single molecule that activates the body’s receptors for GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). The benefit is expected to exceed single-action medication like Wegovy (semalglutide) and Saxenda (liraglutide).

Dosages of Mounjaro (Trizepatide)

The Eli Lilly Pen will offer six doses: (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg)

Will Trizepatide Become a Magic Drug for Weight Loss?

It’s unclear at this early stage if Mounjaro (Trizepatide) will become the “next thing” for weight loss seekers. As we’ve learned in nearly 9 years of treating obesity with various weight loss medications your ability to control insulin through dietary means is the best chance at losing and maintaining the fat loss for the long term.

Are there any Known Glucose-Dependent Insulinotropic Polypeptide (GIP) Agonists?

There are no known natural remedies that can directly increase the production or activity of glucose-dependent insulinotropic polypeptide (GIP). GIP is a hormone produced by K cells in the small intestine in response to food intake, particularly the intake of carbohydrates. While there are a number of natural remedies that may help to improve blood sugar control and potentially increase insulin sensitivity, it is important to note that these remedies are not a substitute for proper medical treatment and should not be used in place of medication prescribed by a healthcare provider.

Some natural remedies that may help to improve blood sugar control and insulin sensitivity include:

  • Exercise: Regular physical activity can help to improve insulin sensitivity and lower blood sugar levels.
  • Weight loss: Losing weight, especially excess abdominal fat, can improve insulin sensitivity and lower blood sugar levels.
  • Healthful diet: Eating a diet rich in fruits, vegetables, whole grains, and lean protein, and low in added sugars and unhealthy fats, can help to improve insulin sensitivity and blood sugar control.
  • Stress management: Chronic stress can interfere with proper blood sugar control and may lead to insulin resistance. Practicing stress-reducing techniques, such as yoga or meditation, may help to improve insulin sensitivity.
  • Getting enough sleep: Adequate sleep is important for proper blood sugar control. Lack of sleep or poor quality sleep can increase the risk of developing insulin resistance and type 2 diabetes.

It is important to speak with a healthcare provider before starting any new natural remedies, as some may interact with medications or have other potential risks or side effects.

Tirzepatide Mounjaro weight loss before and after

Tirzepatide is a medication that is being developed for the treatment of obesity and type 2 diabetes. It is not currently approved for use by regulatory agencies, and there is limited information available about its potential effects on weight loss. However, in the Surpass 2 Trial for its use as a diabetic medication, investigators observed significant weight loss. Even more than what’s been shown with Wegovy / Ozempic. 

When Trizepatide was compared to Ozempic (Wegovy) in diabetes management, weight loss was also measured as an additional outcome. Now, to repeat what we discussed earlier, Trizepatide is a GPL-1 agonist like Ozempic, but it also includes a GIP (Glucose-Dependent Insulinotropic Polypeptide) molecule as well. This is something extra over Ozempic which appears to offer more diabetes management and additional weight loss benefit.

Download the research study summary here: Tirzepatide Wegovy Before and After.

Tirzepatide vs. Semaglutide Diabetes 2 and Weight Loss
Title:Tirzepatide Once Weekly for the Treatment of Obesity | NEJM
Website title:New England Journal of Medicine
Date accessed:December 21, 2022
Author:A Chari

Map With Costa Rica Airport to Age Metrics

M

Conveniently located to San Jose’s Juan Santamaria Airport (SJO) in Escazú, San Jose COSTA RICA.

Age Management & Aesthetics

Various medical weight-loss options. HCG, GLP-1 mimetics, and other alternatives. 

HGH, DHEA, Metformin prescribed based on the 2019 TRIIM Study.

Bioidentical hormone replacement therapies for men and women. 

Order your bioidentical hormone therapy blood testing in the USA.

Platelet rich Plasma for Joint repair

PRP for Joint Repair

Platelet-rich Plasma injections for joint repair. 

P-SHOT PRP Injections

Penile Platelet-rich Plasma cell-based injections for ED. Other ED therapies. 

Micro-needling and Platelet-rich Plasma for entire face rejuvenation. 

Platelet-rich plasma and micro-needling for hair follicle rejuvenation. 

Brand name BOTOX and Fillers. BOTOX, Dysport, and approved facial fillers. 

IV Therapies

Myers’ cocktail, high-dose vitamin C, Chelation, and other common nutrient IV therapies.

Nutrition

Nutrition coaching for improved energy metabolism and fat loss. Keto & plant-based options. 

Save thousands on Growth Hormone Therapy for idiopathic short stature (ISS) in children.

Bio-identical hormone replacement with pellet implants. Women and men can benefit.

Myers’ cocktail, high-dose vitamin C, Chelation, and other common nutrient IV therapies.

Save thousands on Growth Hormone Therapy for idiopathic short stature (ISS) in children.

Testimonials

Bioidentical Hormone Replacement Therapy Reviews

Just Make An Appointment & You're Done!

We cater to medical tourists. Same-day appointments may be available. 

Call Today

+506 2289-2358

Momentum Escazú Centro Medico, #34

Schedule a Virtual Appointment

en_USEN
Scroll to Top